Recursion Stock Soars 17.74% on AI Drug Discovery Partnership

On April 11, 2025, Recursion's stock surged by 17.74% in pre-market trading, reflecting significant investor interest and confidence in the company's recent developments.

Recursion has recently announced a strategic collaboration with Enamine to create AI-enabled targeted compound libraries for drug discovery. This partnership leverages Recursion's AI/ML platform, Recursion OS, and Enamine's REAL Space, the world's largest make-on-demand small molecule collection. The collaboration has resulted in 10 enriched screening libraries comprising over 15,000 newly synthesized compounds, designed to accelerate drug discovery against 100 key clinical targets in challenging biological areas.

By combining Enamine's vast chemical library with Recursion's AI-driven drug discovery platform, the partnership aims to outperform traditional high-throughput screening collections. Recursion's AI technology predicts small molecule compatibility with protein targets, enabling the creation of focused libraries that enhance precision and efficiency in drug discovery. This collaboration not only strengthens Recursion's competitive position in the TechBio space but also provides access to tens of thousands of new compounds for its internal pipeline, while offering commercialization potential through Enamine's distribution of these targeted libraries to pharmaceutical customers.